OmniAb (OABI) Income towards Parent Company (2021 - 2026)
OmniAb's (OABI) quarterly Income towards Parent Company came in at -$7.7 million in Q1 2026, up 57.65% year-on-year from -$4.9 million in Q1 2025, and up 45.64% on a QoQ basis from -$14.2 million in Q4 2025.
OmniAb (OABI) Income towards Parent Company (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Income towards Parent Company data on file, last reported at -$7.7 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 57.65% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was -$54.3 million, a 11.4% increase from a year earlier, with the FY2025 full-year figure at -$64.8 million, down 4.43% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$7.7 million, up from -$14.2 million in the prior quarter.
- Over the last five years, Income towards Parent Company for OABI reached as high as $6.8 million in Q4 2022 and fell as low as -$19.0 million in Q1 2024.
- Historically, Income towards Parent Company has averaged -$12.2 million across 5 years, with a median of -$14.1 million in 2023.
- On a YoY basis, Income towards Parent Company climbed as much as 118.97% in 2022 and fell as far as 470197.48% in 2022.
- Year by year, Income towards Parent Company stood at $6.8 million in 2022, then sank by 306.06% to -$14.1 million in 2023, then climbed by 7.01% to -$13.1 million in 2024, then declined by 8.5% to -$14.2 million in 2025, then surged by 45.64% to -$7.7 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$7.7 million in Q1 2026, -$14.2 million in Q4 2025, and -$16.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | OmniAb | 260.98 Mn | 211.91 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |